Literature DB >> 23803092

Aberrant DNA methylation of P16, MGMT, hMLH1 and hMSH2 genes in combination with the MTHFR C677T genetic polymorphism in gastric cancer.

Hai-Lin Xiong1, Xun-Qi Liu, Ai-Hua Sun, Ying He, Jun Li, Yuan Xia.   

Abstract

Associations of P16, MGMT, hMLH1 and hMLH2 with gastric cancer and their relation with MTHFR status in gastric patients who were confirmed with pathological diagnosis were assessed. Aberrant DNA methylation of P16, MGMT, hMLH1 and hMLH2 and polymorphisms of MTHFR C677T were assayed. The proportional DNA hypermethylation in P16, MGMT, hMLH1 and hMLH2 in cancer tissues was significantly higher than in remote normal-appearing tissues. DNA hypermethylation of P16 and MGMT was correlated with the T and N stages. Individuals with homozygotes (TT) of MTHFR C677T had significant risk of hypermethylation of MGMT in cancer tissues [OR (95% CI)= 3.47(1.41-7.93)]. However, we did not find association between polymorphism in MTHFR C677T and risk of hypermethylation in P16, MGMT, hMLH1 and hMLH2 genes either in cancer or remote normal-appearing tissues. Aberrant hypermethylation of P16, MGMT, hMLH1 and hMLH2 could be predictive of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23803092     DOI: 10.7314/apjcp.2013.14.5.3139

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  12 in total

1.  Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes.

Authors:  Nyasha Chambwe; Matthias Kormaksson; Huimin Geng; Subhajyoti De; Franziska Michor; Nathalie A Johnson; Ryan D Morin; David W Scott; Lucy A Godley; Randy D Gascoyne; Ari Melnick; Fabien Campagne; Rita Shaknovich
Journal:  Blood       Date:  2014-01-02       Impact factor: 22.113

Review 2.  Prognosis value of MGMT promoter methylation for patients with lung cancer: a meta-analysis.

Authors:  Chao Chen; Haiqing Hua; Chenglong Han; Yuan Cheng; Yin Cheng; Zhen Wang; Jutao Bao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 3.  Epigenetics: an emerging player in gastric cancer.

Authors:  Changwon Kang; Ji-Joon Song; Jaeok Lee; Mi Young Kim
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

4.  Genetic polymorphism in DNMTs and gastric cancer: A systematic review and meta-analysis.

Authors:  Marco Neves; Joana Ribeiro; Rui Medeiros; Hugo Sousa
Journal:  Porto Biomed J       Date:  2016-11-21

5.  Relationships between MGMT promoter methylation and gastric cancer: a meta-analysis.

Authors:  Dan Yu; Tao Cao; Ya-Di Han; Fu-Sheng Huang
Journal:  Onco Targets Ther       Date:  2016-10-05       Impact factor: 4.147

Review 6.  The Correlation of MGMT Promoter Methylation and Clinicopathological Features in Gastric Cancer: A Systematic Review and Meta-Analysis.

Authors:  Yong Ding; Qihua Yang; Bojun Wang; Guoliang Ye; Xiaoqiong Tong
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

7.  Influence of MTHFR Genetic Background on p16 and MGMT Methylation in Oral Squamous Cell Cancer.

Authors:  Nadia Ferlazzo; Monica Currò; Angelo Zinellu; Daniela Caccamo; Gaetano Isola; Valeria Ventura; Ciriaco Carru; Giovanni Matarese; Riccardo Ientile
Journal:  Int J Mol Sci       Date:  2017-03-29       Impact factor: 5.923

8.  Association Between hMLH1 Promoter Methylation and Risk of Gastric Cancer: A Meta-Analysis.

Authors:  Peng Ye; Yu Shi; Anling Li
Journal:  Front Physiol       Date:  2018-04-17       Impact factor: 4.566

9.  Detection of aberrant promoter methylation of RNF180, DAPK1 and SFRP2 in plasma DNA of patients with gastric cancer.

Authors:  Xie Zhang; Xuesong Zhang; Beilei Sun; Hongna Lu; Danping Wang; Xiaogang Yuan; Zhigang Huang
Journal:  Oncol Lett       Date:  2014-08-04       Impact factor: 2.967

10.  MLH1 Promoter Methylation and Prediction/Prognosis of Gastric Cancer: A Systematic Review and Meta and Bioinformatic Analysis.

Authors:  Shixuan Shen; Xiaohui Chen; Hao Li; Liping Sun; Yuan Yuan
Journal:  J Cancer       Date:  2018-04-30       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.